Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Low-voltage areas in the left atrium predict atrial fibrillation recurrence after catheter ablation and are associated with adverse outcomes like death, heart failure, and stroke. Detecting low-voltage areas (LVAs) typically requires invasive procedures, highlighting the need for a simple, minimally invasive marker. Vasoactive intestinal peptide (VIP), a neuropeptide released during parasympathetic stimulation, affects electrophysiological remodeling in atrial fibrillation. We hypothesized that serum VIP could serve as a biomarker for detecting LVAs in these patients.
Methods And Results: This prospective, cross-sectional study was conducted at Hokkaido University Hospital between August 2021 and September 2023. We included 108 patients with atrial fibrillation scheduled for catheter ablation. Blood samples were collected during ablation to measure VIP using an ELISA. Electroanatomical mapping identified LVAs, defined as regions with bipolar voltage ≤0.5 mV and occupying >5% of the left atrial surface. Statistical analyses evaluated the relationship between VIP and LVAs. Fifty-one patients (47%) had LVAs, with significantly higher serum VIP levels than those without (335.1 versus 247.7 pg/mL, <0.001). VIP levels and female sex were statistically significant factors of LVAs. Adding VIP to the existing score significantly improved its discrimination (area under the curve: 0.784 versus 0.707, <0.001).
Conclusions: Serum VIP levels are higher in patients with atrial fibrillation with LVAs, suggesting its potential as a noninvasive biomarker for detecting these areas and improving clinical management.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12132879 | PMC |
| http://dx.doi.org/10.1161/JAHA.124.039192 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Artificial Intelligence Automation of Echocardiographic Measurements.
J Am Coll Cardiol
August 2025
Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Cardiology, Kaiser Permanente Santa Clara Medical Center, Santa Clara, California, USA. Electronic address:
Background: Accurate measurement of echocardiographic parameters is crucial for the diagnosis of cardiovascular disease and tracking of change over time; however, manual assessment requires time-consuming effort and can be imprecise. Artificial intelligence has the potential to reduce clinician burden by automating the time-intensive task of comprehensive measurement of echocardiographic parameters.
Objectives: The purpose of this study was to develop and validate open-sourced deep learning semantic segmentation models for the automated measurement of 18 anatomic and Doppler measurements in echocardiography.
Ethanol Infusion of the Vein of Marshall in Catheter Ablation of Persistent Atrial Fibrillation in Patients with Mitral Valve Replacement.
Heart Rhythm
September 2025
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart Lung and Blood Vessel Diseases, Beijing, China. Electronic address:
Background: The effectiveness of ethanol infusion of the vein of Marshall (EIVOM) for persistent atrial fibrillation (AF) in patients with mitral valve replacement (MVR) remains to be determined.
Objectives: This study investigated the effectiveness and safety of EIVOM in catheter ablation of persistent AF in patients with MVR.
Methods: This is a retrospective case-control study.
Key messages on subclinical atrial fibrillation from the ARTESiA and NOAH trials.
Rev Esp Cardiol (Engl Ed)
September 2025
Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Evaluation of Bleeding and Thrombotic Outcomes of Anticoagulation Strategies Upon Intensive Care Unit Admission for Patients with Atrial Fibrillation on Direct Oral Anticoagulants.
J Pharm Pract
September 2025
Department of Pharmacy, Houston Methodist Hospital, TX, USA.
Critically ill adults are more commonly being admitted to intensive care units (ICU) with a recent history of direct oral anticoagulant (DOAC) use. No consensus guidance exists on optimal anticoagulation strategies in critically ill adults with non-valvular atrial fibrillation (NVAF) on DOAC's prior to ICU admission, and there is considerable variability in clinical practice. To evaluate rates of major bleeding and thrombosis between 2 anticoagulation strategies for NVAF upon ICU admission: package insert (continuation of oral or parenteral anticoagulation per manufacturer recommendations) vs non-package insert (prophylactic dosing or delayed therapeutic anticoagulation).
View Article and Find Full Text PDFBipolar radiofrequency ablation for refractory scar-related interatrial septal tachycardias: a multicenter study.
J Interv Card Electrophysiol
September 2025
Electrophysiology Section, Cardiovascular Division, Cleveland Clinic, Cleveland, OH, USA.
Background: Catheter ablation of scar-related interatrial septal atrial tachycardias (IAS-ATs) is challenging and can be refractory to conventional unipolar radiofrequency catheter ablation (RFCA).
Aim: This multicenter study investigated the safety and efficacy of bipolar radiofrequency catheter ablation (Bi-RFCA) in patients with IAS-AT refractory to conventional unipolar RFCA.
Methods: Consecutive patients with scar-related IAS-AT refractory to conventional unipolar RFA across three electrophysiological centers were included in the study.